Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors

• DOI: 10.3389/fcimb.2023.1099063
• Publication Date: 2023-03-03T14:17:54Z
• Authors: Yifan Zhang; Siyuan Cheng; Hua Zou; Zihan Han; Tong Xie; Bohan Zhang; Die Dai; Xiaochen Yin; Yong Liang; Yan Kou; Yan Tan; Lin Shen; Zhi Peng
• Keywords: metagenome sequencing; gastrointestinal cancer; gut microbiome; Microbiology; QR1-502; 3. Good health; Gastrointestinal Microbiome; Cellular and Infection Microbiology; Neoplasms; Colonic Neoplasms; immune-related adverse event; Humans; Prospective Studies; Immunotherapy; Immune Checkpoint Inhibitors; probiotic; Gastrointestinal Neoplasms

The wide application of immune checkpoint inhibitors has significantly improved the survival expectation cancer patients. While immunotherapy brings benefits to patients, it also results in a series immune-related adverse events (irAEs). Increasing evidence suggests that gut microbiome is critical for response and development irAEs.In this prospective study, we recruited 95 patients with advanced/unresectable gastrointestinal cancers treated report comprehensive analysis association irAEs. Metagenome sequencing was used analyze differences bacterial composition metabolic pathways baseline fecal samples.In summary, identified species might be associated occurrence irAEs gastric, esophageal, colon cancers. Ruminococcus callidus Bacteroides xylanisolvens were enriched without severe Several microbial involved urea cycle, including citrulline arginine biosynthesis, We found different types toxicity specific organs endocrine system microbiota profiles. These findings provide basis future mechanistic exploration.